全文获取类型
收费全文 | 410600篇 |
免费 | 54594篇 |
国内免费 | 22975篇 |
专业分类
耳鼻咽喉 | 7101篇 |
儿科学 | 7603篇 |
妇产科学 | 5360篇 |
基础医学 | 35382篇 |
口腔科学 | 5702篇 |
临床医学 | 63939篇 |
内科学 | 84740篇 |
皮肤病学 | 9704篇 |
神经病学 | 29250篇 |
特种医学 | 15679篇 |
外国民族医学 | 198篇 |
外科学 | 65122篇 |
综合类 | 44291篇 |
现状与发展 | 146篇 |
一般理论 | 27篇 |
预防医学 | 22715篇 |
眼科学 | 11476篇 |
药学 | 29039篇 |
299篇 | |
中国医学 | 15575篇 |
肿瘤学 | 34821篇 |
出版年
2024年 | 1581篇 |
2023年 | 8817篇 |
2022年 | 12466篇 |
2021年 | 16976篇 |
2020年 | 16410篇 |
2019年 | 11266篇 |
2018年 | 16761篇 |
2017年 | 15623篇 |
2016年 | 16236篇 |
2015年 | 20328篇 |
2014年 | 30072篇 |
2013年 | 27852篇 |
2012年 | 23967篇 |
2011年 | 26781篇 |
2010年 | 23183篇 |
2009年 | 24056篇 |
2008年 | 18962篇 |
2007年 | 17230篇 |
2006年 | 19933篇 |
2005年 | 17486篇 |
2004年 | 11108篇 |
2003年 | 9508篇 |
2002年 | 8358篇 |
2001年 | 9458篇 |
2000年 | 9403篇 |
1999年 | 10354篇 |
1998年 | 8355篇 |
1997年 | 8195篇 |
1996年 | 7022篇 |
1995年 | 6703篇 |
1994年 | 4825篇 |
1993年 | 3517篇 |
1992年 | 3579篇 |
1991年 | 3239篇 |
1990年 | 2613篇 |
1989年 | 2503篇 |
1988年 | 2142篇 |
1987年 | 1836篇 |
1986年 | 1628篇 |
1985年 | 1318篇 |
1984年 | 891篇 |
1983年 | 731篇 |
1982年 | 626篇 |
1981年 | 524篇 |
1980年 | 440篇 |
1979年 | 396篇 |
1978年 | 328篇 |
1977年 | 396篇 |
1975年 | 277篇 |
1972年 | 302篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
随着腹腔镜肝切除技术的发展与推广,腹腔镜肝切除中的一些难点,如术中出血的控制、解剖性肝切除、巨大肝癌切除、腹腔镜下联合肝脏分割与门静脉支结扎的二步肝切除术(ALPPS)等方面均基本解决。术中超声与荧光染色技术也得到普及。本文就上述问题做一概述,并对腹腔镜肝切除未来发展提出思路,以进一步推动我国腹腔镜肝切除的技术进步。 相似文献
53.
Wei Zhang Zheng Li Feng-Qing Xu Ya-Shuo Ren Shuang-Wang Xu Tong-Sheng Wang 《Journal of Asian natural products research》2019,21(5):426-434
Two new 11-methoxyl substituted triterpenoids, named as mimengosides J (1) and K (2), along with seven known compounds, were isolated from the fruits of Buddleja lindleyana. Their structures were elucidated on the basis of spectroscopic analysis. In addition, the new ones were evaluated for protective effects against damage of SH-SY5Y cells induced by 1-methyl-4-phenylpyridinium ion (MPP+) and the results indicated that those may be one of the candidate compositions of Buddleja lindleyana for the treatment of neurodegenerative disease.
54.
目的对比不同术式对肝内胆管结石再次手术效果,探讨肝段或肝叶切除术的优势。
方法回顾性分析2011年8月至2014年8月收治的79例肝内胆管结石再次手术患者资料,依据术式不同分为肝段(叶)切除术组(甲组,n=38)和非肝段(叶)切除术组(乙组,n=41)两组。应用SPSS 19.0软件对所有临床数据进行统计学分析,手术相关指标等以(
±s)的形式表示,组间比较采用独立t检验;术后并发症发生情况及预后情况等计数资料以例(%)的形式表示,采用χ2检验;P<0.05差异有统计学意义。
结果两组患者术中出血量、手术时间及术后住院时间相比,差异无统计学意义(P>0.05);甲组患者的术后并发症发生率5.3%(2/38)显著低于乙组22.0%(9/41)(P<0.05);甲组残留结石发生率、症状复发率2.6%(1/38)、 0(0/41)均显著低于乙组17.1%(7/41)、 12.2%(5/41)(P<0.05),差异有统计学意义(P<0.05);但两组患者的病死率2.6%(1/38)和0(0/41)相比,差异无统计学意义(P>0.05)。
结论肝段(叶)切除术能够有效改善肝内胆管结石再次手术效果,值得推广。 相似文献
55.
56.
57.
58.
Yuanqing Yao Jun Qian Shunkang Rong Yuwen Huang Bo Xiong Gang Yang Dengqing Zhang Shimin Deng Jie Tan Que Zhu Changming Deng Dichuan Liu Haitao Ran Zhigang Wang Jing Huang 《Ultrasound in medicine & biology》2019,45(2):490-499
Stellate ganglion (SG) modification has been investigated for arrhythmia treatment. In this study, transesophageal SG imaging and intervention were explored using a homemade 30F integrated focused ultrasonic catheter in healthy mongrel canines in vivo. Anatomic details of SGs were ultrasonically imaged and evaluated. SG had a heterogeneous echoic structure and characteristic profiles sketched by hyper-echoic outlines in an ultrasonogram. Left SGs in the experimental group were successfully ablated through the esophagus under ultrasonic guidance provided by the catheter itself. Two weeks after the ablation, the QT and QTc of the experimental group decreased compared with those of the sham group and at baseline (both p values < 0.001). Histologic examination revealed that left SGs were destroyed. No major complications were observed. This approach may be further explored as a method for ganglia remodeling evaluation and as a strategy of ganglia modification for arrhythmia and for other diseases. 相似文献
59.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.